Asset profile
SPY003
Monoclonal antibody
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
74 competitors in this universe: 11 direct rivals (same mechanism and indication), 3 same-class, 60 same-indication; 63 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SPY003: this drug | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Ustekinumab-Stba (Steqeyma) | Approved | — | IL-23 p19, IL-12 p40 | ||
| Ustekinumab-Ttwe (Pyzchiva) | Approved | — | IL-23 p19, IL-12 p40 | ||
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | ||
| Picankibart | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| MT-201 | Phase 2 | Multispecific antibody | TL1A, IL-23 p19 | ||
| SHR-1139 | Phase 2 | Monoclonal antibody | IL-23 p19, IL-36 receptor | ||
| SOR102 | Phase 1 | Biologic (subtype unspecified) | TNF-alpha, IL-23 p19 | ||
| TL-003 | Phase 1 | Multispecific antibody | TL1A, IL-23 p19 | ||
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| HS-20137 | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| ORKA-001 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha |
…and 59 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (1)
June 2027 (1)
What to watch
2029 (1)
March 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.